This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stem cell firms jump on Obama policy plans


WASHINGTON (AP) ¿ Shares of companies developing stem cell therapies surged Friday evening on word that President Obama on Monday is expected to overturn restrictions that have choked funding for academic stem cell research.

President Obama pledged on the campaign trail to overturn the 2001 policy, which bans government funds for research that involves harvesting new embryonic stem cells. President George W. Bush, who set the policy, said the process is immoral because it destroys human embryos.

Industry executives have awaited an executive order from Obama to restore federal funding for the research. But some speculated the withdrawal of former Sen. Tom Daschle for the position of Secretary of Health and Human Services stalled the administration's plans.

A senior administration official said Friday the president will hold an event Monday at the White House to announce the move. The official spoke on condition of anonymity because the policy had not yet been publicly announced Friday.

"This is a very strong and powerful signal that we have a very user-friendly administration for stem cell research, and that will be hugely important going forward," said Richard Garr, president and CEO of Neuralstem Inc, a company working to develop a stem cell therapy for Lou Gehrig's disease.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CYTX $0.25 5.90%
CUR $0.34 -1.50%
GERN $2.69 -0.37%
OSIR $4.95 4.20%
AAPL $92.40 -0.90%


Chart of I:DJI
DOW 17,685.39 +24.68 0.14%
S&P 500 2,046.99 -3.64 -0.18%
NASDAQ 4,701.3840 -15.71 -0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs